This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Diabetes Hospital Kidney Disease 
Cardiovascular Diabetology
MARCH 21, 2025
Mineralocorticoid receptor antagonists (MRAs) are often underutilized in patients with heart failure (HF), particularly those with diabetes and/or chronic kidney disease (CKD). However, the impact of concurren.
Cardiovascular Diabetology
JANUARY 8, 2024
Myocardial infarction (MI), stroke, peripheral arterial disease (PAD), heart failure (HF) and chronic kidney disease (CKD) are common cardiovascular renal diseases (CVRD) manifestations for type 2 diabetes.
Med Page Today
APRIL 3, 2024
(MedPage Today) -- Using a personalized algorithm to identify primary care patients with chronic kidney disease (CKD), type 2 diabetes, and hypertension (the kidney-dysfunction triad) -- plus practice facilitators to help providers deliver guideline.
Cardiometabolic Health Congress
NOVEMBER 16, 2023
Key findings presented at the conference included disparities in access to kidney transplantation and waitlisting based on race and neighborhood characteristics, racial and ethnic differences in incident chronic kidney disease (CKD), and the use of motivational strategies to improve dialysis nonadherence among African American patients.
Stroke Journal
FEBRUARY 1, 2024
Background:The current AHA stroke prevention guidelines give Class 1 recommendations that patients with AIS and diabetes should receive glucose-lowering agents with cardiovascular benefit to reduce risk of MACE. Patients were identified to have diabetes as derived by the Charlson Comorbidity Index ICD 10 codes E10 through E14.
40 
DAIC
JANUARY 18, 2024
Angioplasty procedures below the knee also require x-ray contrast, which can cause damage to kidney function. This is an especially critical issue because many patients undergoing angioplasty procedures below the knee have diabetes and kidney dysfunction. Sinai hospital in New York City by Drs.
105 
Circulation
NOVEMBER 11, 2024
Background:Heart failure (HF) is one of the leading causes of hospitalizations in the States. Results:We included 4,454,273 weighted hospitalizations due to HF for which 380,446 patients (8.5%) had a concurrent diagnosis of hyperkalemia. Circulation, Volume 150, Issue Suppl_1 , Page A4113864-A4113864, November 12, 2024.
40 Circulation
NOVEMBER 11, 2024
Data was obtained from the Hospital Corporation of America (HCA) enterprise-wide database from January 2020 to September 2023 using the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM).
Cardiometabolic Health Congress
NOVEMBER 8, 2023
2023, the American Heart Association (AHA) issued a presidential advisory on the urgency of this systemic disorder involving heart disease, kidney disease, diabetes and obesity. The virtual, self-paced Foundations of Cardiometabolic Health Certificate Course is the first step to attaining the CCHP credential.
Dr. Smith's ECG Blog
SEPTEMBER 5, 2024
She presented to an outside hospital after several days of malaise and feeling unwell. A VSR is more likely to occur in patients who are older, female, hypertensive, have chronic kidney disease, and have no prior history of smoking. At the time of admission, her vital signs were normal. Heart rate was in the 80s.
Open Heart
JULY 20, 2022
Multispecialty interventions included optimising diabetes therapy (haemoglobin A1c-HbA1c pre-MDT 68±11 mmol/mol vs post-MDT 61±9 mmol/mol; p<0.001), deprescribing to reduce anticholinergic burden (pre-MDT 1.85±0.4 post-MDT; p<0.001), reduction of 1586 hospital bed-days and cost savings of £634 400.
Stroke Journal
FEBRUARY 1, 2024
We aimed to compare in-hospital mortality and predictors in stroke patients with secondary rheumatological conditions.Methods:Using the National Inpatient Sample (NIS), we identified patients ≥18 admitted for stroke (Jan 2019 - Dec 2020), stratified into RA, SLE, scleroderma, or vasculitides groups using ICD-10-CM codes.
40 
European Journal of Heart Failure
MARCH 4, 2024
Prior studies were able to show that sodium–glucose cotransporter 2 inhibitors may reduce the incidence of LRTI in patients with type 2 diabetes. Patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) have a high risk of developing LRTI. Patients who developed LRTI had a 2.7-fold
Circulation
NOVEMBER 11, 2024
Patient did not report any symptoms and was hemodynamically stable. He was euvolemic on physical exam.
40 
Circulation: Heart Failure
MARCH 8, 2024
Background:Current prevalence estimates of heart failure (HF) are primarily based on self-report or HF hospitalizations. The prevalence of HF risk factors was high: hypertension, 61.9%; former or current smoking, 53.7%; obesity 34.8%; diabetes; 24.7%; and chronic kidney disease; 22%. were female, 25.6% were Black, 12.8%
DAIC
DECEMBER 8, 2023
AFib causes a variety of symptoms, including fast or chaotic heartbeat, fatigue, shortness of breath, and chest pain, and causes about 450,000 hospitalizations each year, according to the Centers for Disease Control and Prevention. For example, kidney disease is not included in CHA 2 DS 2 -VASc.
DAIC
MARCH 26, 2025
2 Most are balancing multiple comorbidities, such as obesity, diabetes, hypertension and chronic kidney disease (CKD). A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients (REDEFINE-HF). 4 Approximately 6.7 million adults in the U.S. NCT 06008197.
European Journal of Heart Failure
JANUARY 17, 2025
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: a FIDELITY analysis. The incidence of hyperkalaemia leading to hospitalization or study drug discontinuation was low across treatment groups irrespective of diuretic use. Out of 12990 patients, 51.6%
Open Heart
SEPTEMBER 27, 2023
Background Heart failure (HF), type 2 diabetes (T2D) and chronic kidney disease (CKD) commonly coexist. We also estimated rates of healthcare utilisation in primary care and hospital settings in follow-up. We studied characteristics, prognosis and healthcare utilisation of individuals with two of these conditions.
52 
DAIC
APRIL 6, 2024
However, researchers said the drug may be helpful in reducing heart failure risks, including hospitalization, following a heart attack. To have a 25% to 30% reduction in heart failure hospitalizations is pretty clinically meaningful, but if you put it together with all-cause mortality, it was not a positive study for our primary endpoint.”
98 
DAIC
APRIL 30, 2024
Getty Images milla1cf Tue, 04/30/2024 - 12:56 April 30, 2024 — A multicenter study led by Vanderbilt University Medical Center ( VUMC ) and Lipscomb University College of Pharmacy in Nashville has identified a potential new treatment for acute heart failure , a leading cause of hospitalization and death. hospitals from emergency rooms.
105 
Journal of the American Heart Association
JANUARY 23, 2024
BackgroundThe relation between age at diagnosis of type 2 diabetes (T2D) and hospitalization for heart failure (HHF) is unclear. We identified people with new‐onset T2D between April 1, 2005 and March 31, 2015, and matched each person with 3 diabetes‐free adults, according to birth year and sex.
DAIC
APRIL 6, 2024
While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24, About 32% had Type 2 diabetes.
81 
European Journal of Heart Failure
JANUARY 23, 2025
ABSTRACT Aims The sodiumglucose cotransporter 2 inhibitor canagliflozin reduces the risk of heart failure (HF) hospitalization or cardiovascular death and chronic kidney disease (CKD) progression among patients with type 2 diabetes at high cardiovascular risk or with CKD.
40 
DAIC
APRIL 7, 2024
Akshay Desai, MD “Compared to placebo, a single injection of zilebesiran resulted in clinically meaningful reductions in blood pressure at three months when added to commonly used antihypertensive treatments,” said Akshay Desai, MD, MPH , a cardiologist at Brigham and Women’s Hospital in Boston and a study coauthor. “In
111 
Journal of the American Heart Association
JANUARY 19, 2024
BackgroundThis study evaluated the effects of canagliflozin in patients with type 2 diabetes with and without prevalent cardiovascular disease (secondary and primary prevention).Methods Canagliflozin reduced the risk of major adverse cardiovascular events (HR, 0.84 [95% CI, 0.76–0.94])
Journal of the American Heart Association
JANUARY 31, 2024
The primary efficacy end point was the composite of cardiovascular death and hospitalizations for heart failure. The secondary efficacy end points were all‐cause death, cardiovascular death, hospitalizations for heart failure, kidney disease progression, and acute kidney injury.
Hypertension Journal
OCTOBER 11, 2023
BACKGROUND:Despite increasing incidences of hypertension, recent trends in mortality and urgent dialysis following acute hypertension (AHT) remain undetermined.METHODS:This retrospective observational cohort study evaluated 50 316 hospitalized AHT patients from 2010 to 2019, using an administrative claims database in Japan.
40 
Cardiometabolic Health Congress
JULY 25, 2023
Salvatore Carbone, PhD: First, I’d like to point out that obesity is a major risk factor for cardiometabolic disease. There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1]
52 
Journal of the American Heart Association
MARCH 21, 2025
Study end points include mortality, cardiovascular events (hospitalization for acute myocardial infarction or stroke) and limb events (hospitalization for critical limb ischemia or major amputation) and were identified using Veterans Affairs and nonVeterans Affairs encounters.ResultsThe mean age was 70.6 were male, and 18.5%
Stroke: Vascular and Interventional Neurology
NOVEMBER 9, 2023
Factors considered in analysis include patient age, sex, geographic region, Medicaid dual eligibility, disability status prior to age 65, comorbidities, admission length of stay, discharge disposition, and hospital characteristics. 1.378]), and heart failure (1.282 [95%CI, 1.25‐1.315]).ConclusionPatient
40 
Cardiometabolic Health Congress
SEPTEMBER 13, 2024
Measuring eGFR and albuminuria is recommended for assessing kidney disease in all hypertensive patients. Solomon, MD and Muthiah Vaduganathan, MD, MPH (USA) presented results showing that finerenone significantly reduced heart failure hospitalizations and cardiovascular death in patients with HFmrEF and HFpEF.
59 Circulation
NOVEMBER 11, 2024
Background:Empagliflozin is a sodium glucose co-transporter 2 inhibitor that improves cardiovascular outcomes in patients with type 2 diabetes mellitus, chronic kidney disease and heart failure. vs 5.4%), and hospitalization for heart failure (RR 0.66; 95% CI [0.58, 0.76]; P < 0.00001; 3.2%
Stroke Journal
FEBRUARY 1, 2024
Methods:Deidentified administrative discharge data included all individuals admitted to SC hospitals between 2010 and 2019 with ICD-9/10 codes for ischemic stroke. This study aims to assess sociodemographic profile and stroke risk factors among individuals residing in FDs within the predominantly rural state of South Carolina (SC).Methods:Deidentified
40 
DAIC
MAY 16, 2024
Among those ages 65 and older, nearly 50% who underwent limb amputation died within one year after surgery, according to the 2024 Heart Disease and Stroke Statistics: A Report of U.S. and Global Data From the American Heart Association. mg twice daily) combined with low-dose aspirin (81 mg daily).
Stroke Journal
FEBRUARY 1, 2024
Patient- and hospital-level characteristics were analyzed. Outcomes included favorable disposition (discharged to home) and in-hospital mortality.Results:Among 68,975 of stroke MT with recorded NIHSS during the study period (51.1% In-hospital mortality occurred in 17.1% women; mean age, 69.1 [SD, of MT with stenting versus 32.3%
40 
Stroke Journal
JANUARY 30, 2025
We aimed to examine the prevalence of VRFs among young patients with ICH and evaluate for racial and sex disparities in VRF burden.Methods:Data of patients hospitalized with stroke between January 2014 and December 2023 were collected by Get With the Guidelines-Stroke hospitals participating in the Florida Stroke Registry.
40 
European Journal of Heart Failure
DECEMBER 12, 2023
CS patients with anemia without ID were older (73±10 years, p=0.001), had more frequently a history of arterial hypertension (72.8%, p=0.01), diabetes mellitus (47.8%, p=0.001), as well as chronic kidney disease (14.1%, p=0.004) compared to CS patients in other groups.
All About Cardiovascular System and Disorders
OCTOBER 25, 2023
The study documented that catheter ablation for AF in patients with heart failure was associated with a significantly lower rate of a composite endpoint of death from any cause or hospitalization for worsening heart failure, than medical therapy.
DAIC
JANUARY 23, 2024
Atherosclerotic cardiovascular disease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3
Dr. Smith's ECG Blog
FEBRUARY 10, 2025
Written by Jesse McLaren An 80 year old patient with diabetes/hypertension/ cirrhosis had a recent increase in candesartan for their hypertension, and was also on spirolactone and nadolol. Acute hyperkalemia in the emergency department: a summary from a Kidney Disease: Improving Global Outcomes conference. References 1.
118 
Frontiers in Cardiovascular Medicine
MARCH 20, 2025
SGLT-2 inhibitors, initially developed for type 2 diabetes, demonstrate profound cardiorenal and metabolic benefits. This review synthesizes evidence from clinical trials and mechanistic studies to elucidate their roles in cardiovascular diseases, chronic kidney disease, and non-alcoholic fatty liver disease.
52 
Cardiometabolic Health Congress
NOVEMBER 14, 2024
Cardiovascular disease remains the leading cause of death worldwide , claiming 18 million lives annually. 42% of adults are considered obese , increasing their risk of diabetes, hypertension, and cardiovascular issues. In the U.S., SELECT Trial Results : Semaglutide 2.4
103 
Frontiers in Cardiovascular Medicine
FEBRUARY 17, 2025
Individuals with myocardial injury had a higher prevalence of hypertension, diabetes, and dyslipidemia. Myocardial injury is associated with a higher disease severity and risk of in-hospital mortality. IntroductionViral infection by SARS-CoV2 is a pandemic affecting over 600 million people worldwide. times higher risk of death.
40
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content